. Literature search strategy.
Database
Search strategy Pubmed (Medline) *Another intervention group in the three-arm CLOSE consisted of oral anticoagulation, the control group being antiplatelet therapy. 6 The oral anticoagulation group was not described in the present table focusing on the intervention of PFO closure. †Theses numbers were based on the following data provided in the original publication of the RESPECT trial: -Antithrombotic group: 0.34 events per 100 patient-years during a follow-up of 2608 patients-years: N=9. -PFO closure group: 0.48 events per 100 patient-years during a following-up of 3080 patients-years: N=15. The addition of 7 periprocedural events of atrial fibrillation leads to a total number of 22. ‡The number of major bleedings in the RESPECT trial was obtained from the Amplatzer™ PFO Occluder for the Prevention of Recurrent Ischemic Stroke Sponsor's executive summary circulatory system devices panel. * For the meta-analysis presented in Figure 3 , hypermobility (≥10 mm excursion) or ASA (≥15 mm excursion) were analyzed jointly. • Closure group: AF was considered serious in 2 patients, minor in 4. AF was transient in 2 patients; converted to sinus rhythm in 3 patients; sustained in the remaining patient.
• Risk of recurrent stroke: no patient with AF in the closure group had a recurrent stroke. RESPECT • Closure group: 7 had periprocedural AF (serious and nonserious events); all resolved before the patients' discharge from the hospital. 15 patients had AF after the periprocedural period.
• Risk of recurrent stroke: 1/22 patients with AF in the closure group had a recurrent stroke vs 3/9 in the medical group. Gore REDUCE 
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Closure: N=2/60 (3.3%) Antithrombotic: N=0/60 (0.0%)
• Closure group: AF developed in 1 patient 1 day after the procedure and in the other one during follow-up.
• Risk of recurrent stroke: no patient with AF in the closure group had a recurrent stroke. †Theses numbers were based on the following data provided in the original publication of the RESPECT trial: -Antithrombotic group: 0.34 events per 100 patient-years during a follow-up of 2608 patients-years: N=9. -PFO closure group: 0.48 events per 100 patient-years during a following-up of 3080 patients-years: N=15. The addition of 7 periprocedural events of atrial fibrillation leads to a total number of 22. Figure S1 . Guide to the interpretation of a trial sequential analysis (TSA) plot. Adapted from Miladinovic et al. 9 and Brok et al. 10 This plot represents the upper-half of a two-sided trial sequential analysis plot. Each solid curve represents a different TSA, in which each dot corresponds to one study. The horizontal solid green line denotes a cumulative Z-score of 1.96, which corresponds to the classical P=0.05 significance threshold. The vertical solid red line corresponds to the required information size (number of participants and events necessary to detect or reject an a priori assumed intervention effect). The dotted red curve corresponds to the trial sequential monitoring boundary, constructed by using the Lan-DeMets α spending function approach.
Violet curve: False positive (FP) result: even though the cumulative Z-curve crosses the Z=1.96 line, hence suggesting a significant result, it does not cross the monitoring boundary, which indicates a potentially spurious result. Further randomized trials are needed to reach a definitive conclusion.
Blue curve: True positive (TP) result: the cumulative Z-curve crosses the monitoring boundary before reaching the required information size, hence providing strong evidence for the superiority of one intervention over the other.
Grey curve: False negative (FN) result: the cumulative Z-curve does not cross the monitoring boundary or the Z=1.96 line, suggesting a negative result. However, the required information size has not been reached, suggesting that the meta-analysis does not have sufficient statistical power to draw a definitive conclusion. Further randomized trials may be needed to reach a definitive conclusion.
